Brain metastasis-free survival in patients with HER2-positive metastatic breast cancer.Anna S. Berghoff, Rupert Bartsch, Zsuzsanna Bagó-Horváth et al.|Journal of Clinical Oncology|2011Cited by 3
Abstract P6-10-01: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)CF Singer, G Michael, Georg Pfeiler et al.|Cancer Research|2017Cited by 2
Abstract P4-08-05: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 yearsMartin Filipits, Michael Gnant, M. Balic et al.|Cancer Research|2019Cited by 2
P4-17-05: Brain Metastasis Free Survival (BMFS) Differs between Breast Cancer Subtypes.Rupert Bartsch, G.G. Steger, Anna S. Berghoff et al.|Cancer Research|2011Cited by 1
Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).Rupert Bartsch, G. Steger, Anna S. Berghoff et al.|Journal of Clinical Oncology|2011Cited by 1